NASDAQ:ATRI - Atrion Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$604.70 +13.20 (+2.23 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$591.50
Today's Range$589.00 - $612.00
52-Week Range$516.85 - $694.00
Volume15,900 shs
Average Volume8,449 shs
Market Capitalization$1.09 billion
P/E Ratio31.00
Dividend Yield0.82%
Beta0.63
Atrion logoAtrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers, as well as other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Receive ATRI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRI
CUSIP04990410
Phone972-390-9800

Debt

Debt-to-Equity RatioN/A
Current Ratio9.62
Quick Ratio6.95

Price-To-Earnings

Trailing P/E Ratio31.00
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.60 million
Price / Sales7.63
Cash Flow$23.9485 per share
Price / Cash25.25
Book Value$99.57 per share
Price / Book6.07

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$36.59 million
Net Margins23.82%
Return on Equity19.34%
Return on Assets17.32%

Miscellaneous

Employees528
Outstanding Shares1,850,000

Atrion (NASDAQ:ATRI) Frequently Asked Questions

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion announced a quarterly dividend on Tuesday, May 22nd. Investors of record on Friday, June 15th will be given a dividend of $1.20 per share on Friday, June 29th. This represents a $4.80 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, June 14th. View Atrion's Dividend History.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) issued its quarterly earnings results on Wednesday, May, 9th. The medical instruments supplier reported $4.56 earnings per share for the quarter. The medical instruments supplier earned $39.40 million during the quarter. Atrion had a net margin of 23.82% and a return on equity of 19.34%. View Atrion's Earnings History.

When is Atrion's next earnings date?

Atrion is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Atrion.

Who are some of Atrion's key competitors?

Who are Atrion's key executives?

Atrion's management team includes the folowing people:
  • Mr. Emile A. Battat, Exec. Chairman (Age 80)
  • Mr. David A. Battat, Pres & CEO (Age 48)
  • Mr. Jeffery Strickland, VP, CFO, Sec., Treasurer & Principal Accounting Officer (Age 59)

Has Atrion been receiving favorable news coverage?

Headlines about ATRI stock have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atrion earned a daily sentiment score of 0.07 on Accern's scale. They also gave media stories about the medical instruments supplier an impact score of 46.90 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Atrion's major shareholders?

Atrion's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Neuberger Berman Group LLC (5.51%), BlackRock Inc. (5.05%), Dimensional Fund Advisors LP (3.40%), Northern Trust Corp (1.18%), Thomson Horstmann & Bryant Inc. (0.84%) and Schwab Charles Investment Management Inc. (0.40%). Company insiders that own Atrion stock include Emile A Battat, Hugh J Morgan Jr, Jeffery Strickland and Roger F Stebbing. View Institutional Ownership Trends for Atrion.

Which major investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Thomson Horstmann & Bryant Inc., Citigroup Inc., SG Americas Securities LLC, Morgan Dempsey Capital Management LLC, Dimensional Fund Advisors LP, Thrivent Financial for Lutherans and JPMorgan Chase & Co.. View Insider Buying and Selling for Atrion.

Which major investors are buying Atrion stock?

ATRI stock was purchased by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Millennium Management LLC, Northern Trust Corp, UBS Group AG, Piermont Capital Management Inc., A.R.T. Advisors LLC, Rhumbline Advisers and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Atrion.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $604.70.

How big of a company is Atrion?

Atrion has a market capitalization of $1.09 billion and generates $146.60 million in revenue each year. Atrion employs 528 workers across the globe.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at 972-390-9800 or via email at [email protected]


MarketBeat Community Rating for Atrion (ATRI)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Atrion and other stocks. Vote "Outperform" if you believe ATRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.